Showing results (41-50 of 55) with videos related to

Sort By:
Pageof 6
International Journal of Cancer|June 29, 2017
Epigenetic silencing of ASPP1 confers 5-FU resistance in clear cell renal cell carcinoma by preventing p53 activationXingwen Wang, Yiwei Cheng, YiFu Zhu, et al.
Science Translational Medicine|May 7, 2025
Mitigating T cell DNA damage during PARP inhibitor treatment enhances antitumor efficacyJiahao Liu, Xiaofei Jiao, Wei Mu, et al.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|January 31, 2022
Phosphoinositide Conversion Inactivates R-RAS and Drives Metastases in Breast CancerHuayi Li, Lorenzo Prever, Myriam Y Hsu, et al.
Science Translational Medicine|May 27, 2026
Genomic instability drives POSTN<sup>+</sup> myofibroblasts via STING-WNT axis to promote immunosuppression and PARPi resistance in ovarian cancerDan Liu, Kangjia Tao, Chujun Cai, et al.
Oncoimmunology|June 11, 2025
PARP inhibitors accumulate B7-H3 on fibroblasts via blocking autophagic flux to potentiate immune evasion in ovarian cancerTian Fang, Yu Xia, Ying Li, et al.
Eclinicalmedicine|August 26, 2020
Risk factors for developing into critical COVID-19 patients in Wuhan, China: A multicenter, retrospective, cohort studyDan Liu, Pengfei Cui, Shaoqing Zeng, et al.
The Journal of Clinical Investigation|February 2, 2026
SH3BP5L triggers the RAB11A-regulated integrin recycling network implicated in breast cancer metastasisHuayi Li, Maria Chiara De Santis, Francesco A Tucci, et al.
BMC Medicine|May 16, 2024
Exploratory biomarker analysis in the phase III L-MOCA study of olaparib maintenance therapy in patients with platinum-sensitive relapsed ovarian cancerHuayi Li, Zikun Peng, Jianqing Zhu, et al.
The Journal of Pathology|June 18, 2026
Tumor Invasive Border Index (TIBI) in colorectal cancer: linking infiltrative morphology to molecular insightsAkseli Kehusmaa, Jouni Härkönen, Huayi Li, et al.
The Lancet. Oncology|September 14, 2024
Sintilimab combined with bevacizumab in relapsed or persistent ovarian clear cell carcinoma (INOVA): a multicentre, single-arm, phase 2 trialZikun Peng, Huayi Li, Yunong Gao, et al.
Pageof 6